Neos Therapeutics sues Teva and Actavis
02-09-2016
Valeant agrees to license Acanya in Actavis settlement
13-05-2014
jansucko / iStockphoto.com
Canada-based Valeant has agreed to pay $13 million to biotechnology company PDL BioPharma to settle a dispute over royalties.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Valeant, settlement, royalties, PDL BioPharma, patent, biotechnology, Neos Therapeutics, Depomed, diabetes
